GIST adjuvant therapy-some answers and more questions

被引：0
|
作者：
Eisenberg, Burton [1 ]
机构：
[1] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Lebanon, NH 03756 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 08期
关键词：
GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; DOSE IMATINIB; TRIAL; KIT;
D O I：
10.1038/nrclinonc.2009.104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumors. a randomized, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumor.
引用
收藏
页码：441 / 442
页数：3
相关论文
共 40 条
  • [1] Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)
    Casali, Paolo G.
    Fumagalli, Elena
    Gronchi, Alessandro
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (03) : 277 - 284
  • [2] Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions
    Chavez-MacGregor, Mariana
    Mittendorf, Elizabeth A.
    LANCET ONCOLOGY, 2017, 18 (12) : 1568 - 1569
  • [3] Managing GIST in the imatinib era: optimization of adjuvant therapy
    Trent, Jonathan C.
    Subramanian, Meenakshi P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (12) : 1445 - 1459
  • [4] Adjuvant and neoadjuvant therapy for primary GIST
    Eisenberg, Burton L.
    Smith, Kerrington D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 : 3 - 8
  • [5] Prevention of diabetes: more answers, more questions
    Misra, Anoop
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (11) : 831 - 832
  • [6] Adjuvant therapy in primary GIST: state-of-the-art
    Reichardt, P.
    Blay, J. -Y.
    Boukovinas, I.
    Brodowicz, T.
    Broto, J. M.
    Casali, P. G.
    Decatris, M.
    Eriksson, M.
    Gelderblom, H.
    Kosmidis, P.
    Le Cesne, A.
    Pousa, A. L.
    Schlemmer, M.
    Verweij, J.
    Joensuu, H.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2776 - 2781
  • [7] Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting
    Agaimy, Abbas
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2010, 3 (05): : 461 - 471
  • [8] Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)
    Paolo G. Casali
    Elena Fumagalli
    Alessandro Gronchi
    Current Treatment Options in Oncology, 2012, 13 : 277 - 284
  • [9] Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions
    Albuquerque, Kevin
    Chino, Junzo
    Klopp, Ann
    Kamrava, Mitchell
    Beriwal, Sushil
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : 473 - 477
  • [10] Feeding the Critically III: More Questions Than Answers!
    Marik, Paul E.
    Rice, Todd W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (05) : 555 - 556
1234